XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer

Phase 2 Unknown 100 enrolled Epidemiological and Clinical Research Information Network

RandomizedParallel-groupOpen-labelTreatment

The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Cisplatin	Other / unclassified	60 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	80 mg/m2	Intravenous
Subject	S-1	Small molecule	40 mg/m2	Oral